14000 Participants Needed

Selatogrel for Heart Attack

(SOS-AMI Trial)

Recruiting at 567 trial locations
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This study will randomize patients recently discharged from the hospital with a confirmed diagnosis of type 1 acute myocardial infarction (Thygesen et al. 2018) and having additional cardiovascular risk factors.

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications. However, you cannot participate if you are already on oral triple antithrombotic therapy (a combination of blood-thinning medications).

How does the drug Selatogrel differ from other heart attack treatments?

Selatogrel is unique because it is a fast-acting antiplatelet drug that can be administered subcutaneously (under the skin), offering a potentially quicker and more convenient option compared to traditional oral antiplatelet medications used in heart attack management.12345

Who Is on the Research Team?

CT

Clinical Trials

Principal Investigator

Viatris Innovation GmbH

Are You a Good Fit for This Trial?

This trial is for patients who've had a type 1 heart attack within the last 4 weeks and have additional cardiovascular risks like diabetes, kidney disease, or prior heart attacks. They must be able to use an autoinjector and not have severe liver issues, recent strokes, known allergies to P2Y12 drugs like Selatogrel, bleeding risks or be on certain blood thinners.

Inclusion Criteria

I have severe blockage in multiple heart arteries and at least two major health issues like a previous heart attack, diabetes, kidney disease, or poor blood flow in my legs.
I had a heart attack within the last 4 weeks.
Successful self-administered placebo according to the autoinjector instruction for use training during screening.

Exclusion Criteria

I am currently on dialysis.
My liver function is significantly impaired.
I have had a stroke or a mini-stroke in the last 3 months.
See 7 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Randomization and Treatment

Participants are randomized to receive either selatogrel or placebo, and self-administer the study treatment upon experiencing symptoms suggestive of an acute myocardial infarction

Up to 7 days
Visits triggered by self-administration of study treatment

Follow-up

Participants are monitored for safety and effectiveness after treatment, including assessment of clinical status and bleeding events

30 days

What Are the Treatments Tested in This Trial?

Interventions

  • Selatogrel
Trial Overview The study tests Selatogrel against a placebo in people who recently had a heart attack. Participants are chosen at random after leaving the hospital to receive either the actual drug or a dummy injection without knowing which one they're getting.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Placebo Group
Group I: SelatogrelExperimental Treatment1 Intervention
Group II: PlaceboPlacebo Group1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Viatris Innovation GmbH

Lead Sponsor

Idorsia Pharmaceuticals Ltd.

Lead Sponsor

Trials
124
Recruited
36,400+
Antonio Olivieri profile image

Antonio Olivieri

Idorsia Pharmaceuticals Ltd.

Chief Medical Officer since 2024

Not specified

André C. Muller profile image

André C. Muller

Idorsia Pharmaceuticals Ltd.

Chief Executive Officer

Not specified

Citations

Suspected acute coronary syndrome in a theater of operations: first management, medical evacuation, and final diagnosis: experience of the French Medical Army. [2019]
[Treatment of acute myocardial infarct]. [2016]
[Mortality of myocardial infarction]. [2011]
Acute myocardial infarction. Recommendations for medical management and primary angioplasty. [2017]
[Modern treatment in acute coronary syndrome]. [2012]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security